CLINICAL_TRIALS
trial_result
· 2024-07-23
Clinical Trial Update: Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Summary
Phase 3 trial update for tisagenlecleucel in adults with aggressive B-cell non-Hodgkin lymphoma has completed enrollment and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Non-Hodgkin Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2024-07-23